Akèy › Kansè Poumon ki pa ti selil › Kansas › Kansas City
Etid klinik pou Kansè Poumon ki pa ti selil nan Kansas City, KS
11 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Kansas City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Ap rekriteFaz 1
- University of Kansas Medical Center, Kansas City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- University of Kansas Cancer Center, Kansas City
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Kansas Cancer Center, Kansas City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Kansas Hospital, Kansas City
- The University of Kansas Medical Center Medical Office Building, Kansas City
- University of Kansas Hospital Cambridge North Tower A, Kansas City
- ak 1 plis
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- University of Kansas Cancer Center, Kansas City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- University of Kansas Cancer Center, Kansas City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- University of Kansas Cancer Center, Kansas City
- Veteran Administration Eastern Kansas Healthcare, Leavenworth · 21 mi lwen
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- University of Kansas Cancer Center, Kansas City
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Ap rekriteFaz 1/2
- The University of Kansas Cancer Center, Westwood Campus, Kansas City
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
Ap rekriteEtid obsèvasyon
- The University of Kansas Cancer Center, Westwood Campus, Kansas City
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
Ap rekriteEtid obsèvasyon
- The University of Kansas Cancer Center, Westwood Campus, Kansas City
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Kansas City
- Maladi kadyovaskilè14 etid
- Ensifizyans kadyak13 etid
- Obèsite13 etid
- Maladi poumon entèstisyèl13 etid
- Fibroz sistik13 etid
- Kansè nan tete12 etid
- Kansè vejik12 etid
- Leksemi mieloïd egi12 etid
- Kansè pwostat12 etid
- Kansè poumon11 etid
- BPCO9 etid
- Asm8 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.